Form 8-K

Send us Feedback

ISTA Pharmaceuticals (ISTA)

	SUMMARY

	BULLS

	BEARS

	TOPICS

	DATA CENTRAL

	STOCK CHART

	SEC FILINGS

	BALANCE

	INCOME

	CASH FLOW

Annual Reports

Quarterly Reports

8-K

8-K (Mar 26, 2012)8-K (Feb 23, 2012)8-K (Feb 17, 2012)8-K (Jan 17, 2012)8-K (Jan 4, 2012)8-K (Dec 22, 2011)8-K (Dec 6, 2011)8-K (Nov 4, 2011)8-K (Nov 2, 2011)8-K (Oct 18, 2011)8-K (Aug 8, 2011)8-K (Jul 29, 2011)8-K (May 16, 2011)8-K (May 5, 2011)8-K (Apr 14, 2011)8-K (Apr 6, 2011)8-K (Feb 23, 2011)8-K (Feb 10, 2011)8-K (Jan 6, 2011)8-K (Dec 21, 2010)8-K (Dec 9, 2010)8-K (Nov 2, 2010)8-K (Oct 18, 2010)8-K (Sep 1, 2010)8-K (Aug 4, 2010)8-K (Jun 30, 2010)8-K (Apr 30, 2010)8-K (Mar 18, 2010)8-K (Feb 23, 2010)8-K (Feb 9, 2010)8-K (Feb 8, 2010)8-K (Feb 5, 2010)8-K (Dec 17, 2009)8-K (Dec 11, 2009)8-K (Nov 3, 2009)8-K (Aug 26, 2009)8-K (Aug 5, 2009)8-K (May 7, 2009)8-K (Mar 6, 2009)8-K (Feb 26, 2009)8-K (Feb 19, 2009)8-K (Feb 10, 2009)8-K (Feb 9, 2009)8-K (Dec 24, 2008)8-K (Nov 3, 2008)8-K (Oct 30, 2008)8-K (Sep 30, 2008)8-K (Aug 7, 2008)8-K (Jul 3, 2008)8-K (Apr 30, 2008)8-K (Apr 10, 2008)8-K (Mar 31, 2008)8-K (Mar 6, 2008)8-K (Feb 13, 2008)8-K (Nov 1, 2007)8-K (Sep 27, 2007)8-K (Aug 21, 2007)8-K (Aug 1, 2007)8-K (Jun 27, 2007)8-K (Apr 26, 2007)8-K (Mar 14, 2007)8-K (Mar 6, 2007)8-K (Feb 20, 2007)8-K (Feb 8, 2007)8-K (Feb 2, 2007)8-K (Nov 2, 2006)8-K (Oct 31, 2006)8-K (Oct 25, 2006)8-K (Sep 29, 2006)8-K (Aug 3, 2006)8-K (Jun 28, 2006)8-K (Jun 22, 2006)8-K (Jun 16, 2006)8-K (Jun 2, 2006)8-K (May 8, 2006)8-K (May 1, 2006)8-K (Mar 15, 2006)8-K (Feb 23, 2006)8-K (Dec 22, 2005)8-K (Nov 8, 2005)8-K (Oct 14, 2005)8-K (Sep 14, 2005)8-K (Aug 31, 2005)8-K (Aug 4, 2005)8-K (Jul 12, 2005)8-K (May 10, 2005)8-K (Mar 30, 2005)8-K (Mar 2, 2005)8-K (Feb 17, 2005)8-K (Jan 21, 2005)8-K (Jan 11, 2005)8-K (Dec 28, 2004)8-K (Dec 15, 2004)8-K (Nov 18, 2004)8-K (Oct 22, 2004)8-K (Oct 21, 2004)8-K (Sep 28, 2004)8-K (Sep 13, 2004)8-K (Aug 13, 2004)8-K (Aug 12, 2004)8-K (Aug 10, 2004)8-K (Aug 6, 2004)8-K (Aug 4, 2004)8-K (Jul 15, 2004)8-K (Jun 21, 2004)8-K (Jun 9, 2004)8-K (May 26, 2004)8-K (Apr 23, 2004)8-K (Feb 26, 2004)8-K (Oct 17, 2003)8-K (Oct 9, 2003)8-K (Jul 29, 2003)8-K (Jul 22, 2003)8-K (Apr 25, 2003)8-K (Apr 23, 2003)8-K (Apr 9, 2003)8-K (Mar 18, 2003)8-K (Dec 20, 2002)8-K (Dec 12, 2002)8-K (Dec 3, 2002)8-K (Sep 25, 2002)8-K (Jul 9, 2002)8-K (Jun 26, 2002)8-K (Jun 11, 2002)8-K (May 6, 2002)8-K (Jan 2, 2002)

Other

ISTA Pharmaceuticals 8-K 2012

Documents found in this filing:

Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 23, 2012

ISTA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)


Delaware	001-35396	33-0511729
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

50 Technology Drive, Irvine, California		92618
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (949) 788-6000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

x	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01

Other Events.

On April 23, 2012, the Company issued a press release, which is attached hereto as Exhibit 99.1 and is incorporated herein by reference, announcing the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with the Company’s pending acquisition by Bausch & Lomb Incorporated, a New York corporation (“Parent”), pursuant to the Agreement and Plan of Merger dated as of March 26, 2012, by and among the Company, Parent, and Inga Acquisition Corporation, a Delaware corporation and wholly-owned subsidiary of Parent. Completion of the transaction remains subject to the satisfaction of certain conditions, including approval of the Company’s stockholders.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits.


Exhibit Number		Description

99.1		Press Release, dated April 23, 2012

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	ISTA PHARMACEUTICALS, INC.

April 24, 2012	By:	/s/ Lauren P. Silvernail
		Chief Financial Officer and Vice President, Corporate Development

EXHIBIT INDEX


Exhibit Number		Description

99.1		Press Release, dated April 23, 2012

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.

Mobile | Advertise | Licensing & Partnerships | Blogger Tools | Jobs

ISTA Pharmaceuticals (ISTA)

Annual Reports

Quarterly Reports

8-K

Other

Documents found in this filing: